Bracco Build U.S. Contrast Media Facility

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for injectable contrast media in Sanford, North Carolina. Expected to create 200 jobs, the investment marks a significant milestone in Bracco’s global manufacturing strategy, expanding production capacity and strengthening supply chain resilience in the United States, the company’s largest market.

“For almost 100 years, Bracco has been guided by one purpose: improving people’s lives. The United States is our largest market and home to many of the patients we serve,” said Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging. “Producing injectable contrast media here in Sanford brings our supply closer to American hospitals and patients and makes it even more resilient. We chose North Carolina for its talent and life sciences ecosystem. As a family-owned company, we invest for the long term, and we look forward to growing with the Sanford community for decades to come.”

Contrast Media Facility

The new state-of-the-art sterile manufacturing facility will complement Bracco’s established production operations across Europe, Asia and Canada, creating a more geographically diversified and resilient manufacturing network. With additional sterile manufacturing capacity in the United States, Bracco will be better positioned to meet growing demand, respond to customer needs and support reliable access to injectable contrast media used in diagnostic imaging.

The facility will be developed with a focus on advanced manufacturing capabilities and the high standards of quality that underpin Bracco’s global operations, supporting the company’s mission to advance diagnostic imaging and improve patient care. 

Bracco selected Sanford, North Carolina, for its skilled workforce, established life sciences ecosystem and supportive environment for advanced manufacturing. The investment is expected to create 200 jobs across manufacturing, engineering, technical operations, quality, warehousing and administrative functions, contributing to the continued growth of the state’s life sciences sector.

The project builds on Bracco’s nearly century-long history of innovation in diagnostic imaging and reflects its continued investment in the manufacturing capabilities needed to support healthcare professionals and patients worldwide.

Source link

The Fenix Group Names Brian Turner as CTO

The Fenix Group Specialty Performance Coatings has appointed Brian Turner as Chief Technology Officer. In his new role, Turner will oversee the integration of research and development activities across the company’s four manufacturing facilities in the United States, with a focus on improving product development, technical consistency, and innovation across its industrial and concrete coatings businesses. 

The company stated that the appointment is in line with its strategy of coordinating technical capabilities across its portfolio of specialty coatings brands. Turner brings nearly 30 years of experience in coatings and construction materials, with a background spanning innovation management, collaborative leadership, and product development. He holds a bachelor’s degree in chemistry from Pennsylvania State University and holds Six Sigma certification. 

R&D Coordination Across a Multi-Site Manufacturing Network 

The Fenix Group manufactures specialty industrial and concrete coatings for mid-market original equipment manufacturers and contractors. Its brand portfolio includes “Burke”, “Concrete Coatings”, “National Coatings”, “Sierra”, “SureCrete”, “TCI Coatings”, and “TK Products”. The company operates manufacturing facilities in Minnetonka, Minnesota; Galesburg, Illinois; Dade City, Florida; and Lubbock, Texas. 

The appointment of a dedicated Chief Technology Officer is intended to support product consistency, formulation development, and technical collaboration across the company’s multi-site network. 

Source link